Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q3 2015 · 10-Q
Revenue$58.00K$58.00K+1.8% vs Q3 2014 Net Income-$2.74M-$2.74MN/M vs Q3 2014 EPS Diluted-$0.23-$0.23N/M vs Q3 2014 Operating Income-$6,409,552N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$5,701,693N/M Margins · derivedOperating margin-11051.0%−4138.3 pt vs Q3 2014
Net margin-4716.9%+4713.3 pt vs Q3 2014
ended Sep 30, 2015 · filed Nov 9, 2015 · 40 d after period end